|

eftilagimod alfa Clinical Trials

1 actively recruiting trial across 1 location

Also known as: IMP321, LAG-3Ig, efti, eftilagimod alpha

Pipeline

Phase 3: 1

Top Sponsors

  • Immutep S.A.S.1

Indications

  • Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)1
  • Lung Cancer1
  • Cancer1

Louisville, Kentucky1 trial

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

Norton Cancer Institute - Audubon

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.